Comparative Pharmacology
Head-to-head clinical analysis: DEMULEN 1 35 28 versus MONO LINYAH.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEMULEN 1 35 28 versus MONO LINYAH.
DEMULEN 1/35-28 vs MONO-LINYAH
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination estrogen-progestin contraceptive; suppresses gonadotropin release, inhibiting ovulation; increases cervical mucus viscosity, impeding sperm penetration; alters endometrial receptivity.
Monoclonal antibody that binds to and inhibits the activity of interleukin-23 (IL-23), a pro-inflammatory cytokine involved in immune-mediated inflammatory diseases.
One tablet (contains 1 mg ethynodiol diacetate and 35 mcg ethinyl estradiol) orally once daily at the same time each day for 21 days, followed by 7 days of placebo or no tablets.
10 mg orally once daily
None Documented
None Documented
Ethinyl estradiol: 17.4 ± 5.6 h (terminal); norethindrone: 10.9 ± 1.6 h (terminal); clinically, steady-state achieved within 5-7 days.
Terminal elimination half-life is 3–5 hours in adults; prolonged to 8–15 hours in renal impairment (CrCl <30 mL/min) and in neonates.
Renal 50% (metabolites), fecal 50% (biliary elimination of conjugates).
Predominantly renal as unchanged drug (≥90%); minor biliary/fecal (<5%).
Category C
Category C
Combination Oral Contraceptive
Combination Oral Contraceptive